Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Inclusion Criteria: * Has a histologically confirmed adenocarcinoma of the prostate, for which endocrine therapy is indicated * Has a current tumour, nodule and metastasis (TNM) staging within 12 weeks prior to treatment start and, if clinically indicated a bone scan * Has a PSA level meeting one of these criteria: 1. For treatment-naïve patients: Screening PSA level should be ≥2 ng/mL. 2. For patients with recurrence after radical prostatectomy: Patients should have a serum PSA increase of ≥0.2 ng/mL from the previous test on two consecutive measurements 3. For patients with recurrence after radiotherapy or cryotherapy: Patients should have a serum PSA (two measurements) to be \>2 ng/mL higher than a previously confirmed PSA nadir * Has a screening serum testosterone level above the lower limit of normal range in an elderly male population, globally defined as \>150 ng/dL * Has an Eastern Cooperative Oncology Group score of ≤2 * Has a life expectancy of at least one year Exclusion Criteria: * Has had previous or is currently under hormonal management of prostate cancer * Is considered to be a candidate for curative therapy i.e. radical prostatectomy or radiotherapy during the trial period * Has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy * Has a marked baseline prolongation of QT/QTcF interval (e.g. repeated demonstration of a QTcF interval \>450 ms) * Has a history of risk factors for Torsade de Pointes ventricular arrhythmias (e.g. heart failure, hypokalemia, or family history of Long QT Syndrome) * Has a previous history or presence of another malignancy, other than prostate * Currently receiving chronic treatment with intramuscular medication injected into the ventrogluteal or dorsogluteal muscle * Has received an investigational drug within the last 28 days preceding the Screening Visit or longer if considered to possibly influence the outcome of the current trial